About: Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on September 2008

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2008 (ast) наукова стаття, опублікована у вересні 2008 (uk) مقالة علمية نشرت في سبتمبر 2008 (ar) scientific article published on September 2008 (en)
publication date	wds:Q37221577-1046700A-CEAA-4C40-8616-82DA904719E6
publication date	2008-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37221577-CE84CCA5-259F-4785-9803-E1594F859C38
language of work or name	English
cites work	wds:Q37221577-188CD19C-905D-4CA0-A849-3388831D167E wds:Q37221577-262656D6-E64E-44F1-B3E6-8F82EB31CE11 wds:Q37221577-4830B448-18E1-47AF-9103-F219FF1D47AB wds:Q37221577-4D5C3E18-054C-4C57-A9F3-2D504EEBA302 wds:Q37221577-776B4E4C-155E-4979-BF75-5C54BD66D192 wds:Q37221577-813DFF14-F396-4C1E-99FA-4095A934E614 wds:Q37221577-85FDB192-2D74-4E29-82D8-1608C7E5BBEE wds:Q37221577-880ACDF6-52E0-4D48-BF5B-94B0D9AA3CE0 wds:Q37221577-8C5959CF-3187-4659-8522-E23B6E6450C2 wds:Q37221577-A1F30E7F-B761-45C8-9B2D-6689818E1586 wds:Q37221577-A99F8910-A2A1-4691-83C1-FDFBEA0745A8 wds:Q37221577-AA445263-66EE-42CE-AF1B-5CBBADDCDBA9 wds:Q37221577-AE651E17-C8C9-4F62-B26F-7E7751438A3A wds:Q37221577-B4D240DA-C588-47F2-AC9C-F6AB5BE5F3C8 wds:Q37221577-B8E91619-02AF-4A51-B038-2B11B6788275 wds:Q37221577-C6D02AC6-B50B-4E5E-99E7-5087FAF1C3C0 wds:Q37221577-F4F3638F-7113-4505-8F0D-9B637E26D26C
cites work	Corneal and conjunctival changes caused by commonly used glaucoma medications Prevalence of dry eye among the elderly Reliability and validity of the Ocular Surface Disease Index Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review Effect of timolol with and without preservative on the basal tear turnover in glaucoma In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy Duration of IOP reduction with travoprost BAK-free solution Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride Ocular symptoms and signs with preserved and preservative-free glaucoma medications Ocular surface disease index for the diagnosis of dry eye syndrome Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia
author name string	wds:Q37221577-00DC293F-6A53-472E-B18C-3FDD4C4AC8C2 wds:Q37221577-5FC5C25F-6324-454C-8CB1-E6310050850D wds:Q37221577-6FF82489-D037-4752-9D87-9BEFF34E0C3D wds:Q37221577-9A3F6759-3E8F-4A09-B983-6CDD05BB7C9B
author name string	Jeanette A Stewart William C Stewart James H Peace J Charles Henry
rdfs:label	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy (en) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy (ast) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. (nl)
skos:prefLabel	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy (en) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy (ast) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. (nl)
name	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy (en) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy (ast) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. (nl)
title	wds:Q37221577-C14F41E1-3BC4-4770-A682-C979879047DF
title	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy (en)
page(s)	wds:Q37221577-64B4DBEA-932F-4EA8-8335-34E6C86BA109
page(s)	613-621
instance of	wds:Q37221577-2AA6B2B4-5BF3-40C6-9AC6-AC66062506EE
instance of	scholarly article
PubMed ID	wds:Q37221577-C0778485-21B3-4439-AD89-DC68C7C2E2CD
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19668762
PubMed ID	19668762
published in	wds:Q37221577-3FE2596C-B1EB-404E-BE9B-9C8A2DE00B56
published in	Clinical Ophthalmology
issue	wds:Q37221577-370B3E73-19DA-4FF2-B09F-2C10722324DA
volume	wds:Q37221577-66F400E9-DFBE-4EC1-BBB2-A4F111A37A76
issue	3
volume	2
DOI	wds:Q37221577-8B5E80E1-8DCA-4D84-A252-B6F549D11E22
DOI	http://dx.doi.org/10.2147/OPTH.S3881
DOI	10.2147/OPTH.S3881
PMCID	wds:Q37221577-3355A51B-739D-4B1A-A01B-4DB1970EEDDB
PMCID	2694010
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q37221577
is cites work of	Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases Challenges in the clinical measurement of ocular surface disease in glaucoma patients Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software